Nalaganje...
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia...
Shranjeno v:
| izdano v: | BioDrugs |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544486/ https://ncbi.nlm.nih.gov/pubmed/25859858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0122-9 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|